Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...
Reexamination Certificate
2002-02-06
2008-12-30
Fetterolf, Brandon J (Department: 1642)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Reexamination Certificate
active
07470429
ABSTRACT:
A method for increasing the target-specific toxicity of a drug is effected by pretargeting an enzyme to a mammalian target site, and then administering a cytotoxic drug known to act at the target site, or a prodrug form thereof which is converted to the drug in situ, which drug is also detoxified to form an intermediate of lower toxicity using said mammal's ordinary metabolic processes, whereby the detoxified intermediate is reconverted to its more toxic form by the pretargeted enzyme and thus has enhanced cytotoxicity at the target site. Further enhancement can be achieved by pretargeting an enzyme which converts the prodrug to the cytotoxic drug at the target site. Kits for use with the method also are provided. The method and kits permit lower doses of cytotoxic agents, maximize target site activity and minimize systemic side effects.
REFERENCES:
patent: 3927193 (1975-12-01), Hansen et al.
patent: 4036945 (1977-07-01), Haber
patent: 4331647 (1982-05-01), Goldenberg
patent: 4348376 (1982-09-01), Goldenberg
patent: 4361544 (1982-11-01), Goldenberg
patent: 4444744 (1984-04-01), Goldenberg
patent: 4460459 (1984-07-01), Shaw et al.
patent: 4460561 (1984-07-01), Goldenberg
patent: 4468457 (1984-08-01), Goldenberg et al.
patent: 4735210 (1988-04-01), Goldenberg
patent: 5256395 (1993-10-01), Barbet et al.
patent: 5851527 (1998-12-01), Hansen
patent: 6264917 (2001-07-01), Klaveness et al.
patent: 6312694 (2001-11-01), Thorpe et al.
patent: 6962702 (2005-11-01), Hansen et al.
patent: 7074405 (2006-07-01), Hansen et al.
patent: 0 501 215 (1992-02-01), None
patent: 91/09134 (1991-06-01), None
patent: WO 9108770 (1991-06-01), None
patent: 96/20011 (1996-07-01), None
patent: WO 9640245 (1996-12-01), None
patent: 97/41898 (1997-11-01), None
patent: 99/42593 (1999-08-01), None
patent: 99/66951 (1999-12-01), None
[Fundamental Immunology 212 (William E. Paul, M.D. ed., 3rd ed. 1993)].
Trail et al., “Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates”, Science, 1993, pp. 212-215, vol. 261.
Trail et al., “Effect of Linker Variation on the Stability, Potency, and Efficacy of Carcinomareactive BR64-Doxorubicin Immunoconjugates”, Cancer Res., 1997, pp. 100-105, vol. 57.
Arcamone, “Properties of Antitumor Anthracyclines and New Developments in Their Application: Cain Memorial Award Lecture”, Cancer Res., 1985, p. 5995, vol. 45.
Potter et al., “Isolation and Partial Characterization of a cDNA Encoding a Rabbit Liver Carboxylesterase That Activates the Prodrug Irinotecan (CPT-11)”, Cancer Res., 1998, pp. 2646-2651, vol. 58.
Potter et al., “Cellular Localization Domains of a Rabbit and Human Carboxylesterase: Influence on Irinotecan (CPT-11) Metabolism by the Rabbit Enzyme”, Cancer Res., 1998, pp. 3627-3632, vol. 58.
Wang et al., “Specific Activation of Glucuronide Prodrugs by Antibody-Targeted Enzyme Conjugates for Cancer Therapy”, Cancer Res., 1992, pp. 4484-4491, vol. 52.
Bakina et al., “Intensely Cytotoxic Anthracycline Prodrugs: Glucuronides”, J. Med Chem., 1997, pp. 4013-4018, vol. 40.
Schmidt et al., “Glucuronide Prodrugs of Hydroxy Compounds For Antibody Directed Enzyme Prodrug Therapy (Adept) A Phenol Nitrogen Mustard Carbamate”, Bioorg. Med Chem. Lett., 1997, pp. 1071-1076, vol. 7.
Gupta et al., “Pharmacokinetic Modulation of Irinotecan and Metabolites by Cyclosporin A”, Cancer Res., 1996, pp. 1309-1314, vol. 56.
Gupta et al., “Modulation of Glucuronidation of SN-38, The Active Metabolite of Irinotecan, by Valproic Acxid and Phenobarbital”, Cancer Chemother. Pharmacol., 1997, pp. 440-444, vol. 39.
Melton et al., “Antibody-Directed Enzyme Prodrug Therapy (ADEPT) Review Article”, Drugs of the Future 1996, pp. 167-181, vol. 21, No. 2, Barcelona, Spain.
Hay et al., “Antibody-Directed Enzyme Prodrug Therapy (ADEPT)”, Drugs of the Future, 1996, pp. 917-931, vol. 21, No. 9.
Takayama et al., “Synthesis of a New Class of Camptothecin Derivatives, The Long-Chain Fatty Acid Esters of 10-Hydroxycampothecin, as a Potent Prodrug Candidate, and Their In Vitro Metabolic Conversion by Carboxylesterases”, Bioorganic & Medicinal Chemistry Letters, 1998, pp. 415-418, vol. 8, No. 5, Oxford, Great Britain.
Danks et al., “Comparison of Activation of CPT-11 by Rabbit and Human Carboxylesterases for Use in Enzyme/Prodrug Therapy”, Clinical Cancer Research, 1999, pp. 917-924, vol. 5, No. 4.
Leu et al., “Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT)”, Journal of Medicinal Chemistry, 1999, pp. 3623-3628, vol. 42, No. 18.
Griffiths Gary L.
Hansen Hans J.
Fetterolf Brandon J
Immunomedics Inc.
Nakashima Richard A.
LandOfFree
Methods and compositions for increasing the target-specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for increasing the target-specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for increasing the target-specific... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4043599